SRNE Sorrento Therapeutics Inc.

8.07
+0.07  (+1%)
Previous Close 8
Open 8.05
52 Week Low 5.17
52 Week High 17.25
Market Cap $2,405,991,472
Shares 298,099,574
Float 293,559,311
Enterprise Value $2,428,894,604
Volume 1,578,886
Av. Daily Volume 4,712,749
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Abivertinib
COVID-19
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
SEMDEXA (SP-102)
Lumbosacral radicular pain (sciatica)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
ABIVERTINIB (STI-5656)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Abivertinib
Prostate cancer
Phase 2
Phase 2
IND for Phase 2 trial to be filed 4Q 2021.
COVI-MSC (MSC-COV-202BR)
COVID-19 / Acute Respiratory Distress Syndrome
Phase 2
Phase 2
Phase 2 trial initiated enrollment September 3, 2021. Phase 2 US and long haul studies to begin enrollment in 2021.
Enbrel
Rheumatoid Arthritis
Phase 1b
Phase 1b
Phase 1b initial data published August 23, 2021.
Resiniferatoxin
OsteoArthritis (OA) Knee Pain
Phase 2
Phase 2
Phase 2 trial planned following FDA clearance.
STI-2099 (COVI-DROPS)
COVID-19
Phase 2
Phase 2
Phase 2 trial dosing initiated July 21 2021.
ESG-401
Solid Tumors
Phase 1
Phase 1
IND filing to be initiated before end of 2021.
STI-3031
Urothelial carcinoma
Phase 2a
Phase 2a
Phase 2a trial planned.
STI-6129
AL Amyloidosis
Phase 1b
Phase 1b
Phase 1b initiation of dosing announced March 19, 2021.
STI-2020 (COVI-AMG)
COVID-19
Phase 1
Phase 1
Phase 1 trial currently evaluating.
STI-2099
Healthy volunteers and outpatients with mild COVID-19
Phase 1
Phase 1
Phase 1 trial planned.
Resiniferatoxin
Intractable Pain Associated with Cancer
Phase 1b
Phase 1b
Phase 1b data released September 22, 2020.
STI-1499 (COVI-GUARD)
COVID-19
Phase 1
Phase 1
Phase 1 trial planned.
Anti-CD38 CAR-T
Multiple Myeloma
Phase 1
Phase 1
Phase 1 trial ongoing.
CYNK-001
COVID-19 Coronavirus
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence immediately - noted April 2, 2020.
STI-4398
Coronavirus COVID-19
Phase 1
Phase 1
Phase 1 IND filing due to be filed in the coming months - noted March 20, 2020.
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
Approved
Approved
Approval announced February 28, 2018.

Latest News

  1. Columbus, Ohio, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that, subsequent to the Company's recent appointment of five independent Directors to its Board of Directors (the "Board"), that it held its first Special Meeting of the Board of Directors on September 17, 2021 (the "Special Meeting") virtually with all seven members in attendance including Ian James, Stephen Letourneau, Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD. 

    "I'm incredibly proud of the progress we've made and the initiatives we're working on," commented…

    Columbus, Ohio, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that, subsequent to the Company's recent appointment of five independent Directors to its Board of Directors (the "Board"), that it held its first Special Meeting of the Board of Directors on September 17, 2021 (the "Special Meeting") virtually with all seven members in attendance including Ian James, Stephen Letourneau, Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD. 

    "I'm incredibly proud of the progress we've made and the initiatives we're working on," commented Ian James, Chief Executive Officer of Better For You Wellness. "Over the last eight weeks at the helm, the Company has begun the process for a name and ticker change, appointed five accomplished and renowned Independent Directors to its Board, and has now made further meaningful progress towards capital raising, M&A opportunities, up-listing, and more."

    The major initiatives that were discussed, voted upon, and unanimously approved at the Special Meeting mark significant milestones in the Company's growth plan and up-listing initiatives:

    Appointment of David Deming as Secretary of the Board

    At the Special Meeting, the Board unanimously approved the appointment of David Deming as Secretary of the Board, effective immediately. 

    ​​David Deming serves as Partner and Chief Operating Officer of ID Fund LLC, an investor-directed firm for accredited investors. Mr. Deming formerly served as a director of Sorrento Therapeutics Inc. (NASDAQ:SRNE), a clinical stage and commercial-stage biopharmaceutical company that develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases, and has served on the board of numerous other public and private biotechnology companies, in addition to serving on the Board of Trustees of Hobart and William Smith Colleges for over a decade. Mr. Deming started fis career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College in 1975.

    Term Sheet for Purchase of up to $30,500,000 of the Company's Common Stock

    At the Special Meeting, the Board unanimously approved the Company's execution of a Term Sheet with Williamsburg Venture Holdings, LLC (the "Term Sheet") for the purchase of up to $30,000,000 of the Company's Common Stock in a registered offering, as well as the purchase of up to $500,000 of the Company's Common Stock in a private placement prior to the registered offering.  

    Williamsburg Venture Holdings, LLC is a NYC-based private investment vehicle. 

    Subsequent to the Special Meeting of the Board, the Company entered into the Term Sheet and is in the process of preparing and negotiating Definitive Agreements with Williamsburg Venture Holdings, LLC. 

    The Company intends to use proceeds from the private placement for legal costs, filing fees, and more. The Company intends to use the proceeds from the registered offering for mergers, acquisitions, and more. 

    Retention of Securities Counsel

    At the Special Meeting, the Board unanimously approved the Company's execution of an Engagement Agreement with Carter Ledyard & Milburn LLP (the "Engagement Agreement") for legal services related to mergers, acquisitions, or business combination transactions, as well as the Company's up-listing to a national securities exchange such as the NASDAQ or NYSE. 

    Carter Ledyard & Milburn LLP is a general practice law firm headquartered on Wall Street with clients around the globe and a foundation of over 165 years of legal service. 

    Subsequent to the Special Meeting of the Board, the Company entered into the Engagement Agreement. 

    Technology, Media and Advertising Engagements

    At the Special Meeting, the Board unanimously approved the Company's execution of multiple agreements with SRAX, Inc. (NASDAQ:SRAX) (the "Technology, Media and Advertising Engagements") for 12 months of technology, media, and advertising services that will assist the Company in communicating with existing and prospective investors. 

    SRAX, Inc. is a technology company that leverages investor data and intelligence to maximize awareness and communication.

    Subsequent to the Board's Special Meeting, the Company entered into the Technology, Media and Advertising Engagements. 

    Face-to-Face Meeting

    At the Special Meeting, the Board further scheduled an in-person Board of Directors meeting on October 1, 2021 in Columbus, Ohio. Items expected to be discussed at the upcoming meeting include the evaluation of investment banking and capital markets advisory firms, and the formation of a Candidate Search Committee for potential members of a Compensation Committee and an Audit Committee.

    Further to the Company's press release on August 19, 2021, The Company's name change from Fast Track Solutions, Inc. to Better For You Wellness, Inc. (the "Name Change") has become effective in the State of Nevada. The Company is still awaiting notification from FINRA that the Name Change has been processed. The Company is actively exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. 

    "The Company intends to continue making rapid progress on its track to building a best-in-class leader in the plant-based wellness space and shall continue its parallel pursuit of up-listing to a national securities exchange such as the NASDAQ or NYSE," added Ian James. "On behalf of the entire Board, we are passionate about what we are building and look forward to what's next for the Company."

    About Better For You Wellness, Inc.

    Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) is a Columbus, Ohio-based blank-check company that is exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. Learn more at https://betterforyouwellness.com/.

    Forward-Looking Statements

    This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could," "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed with SEC (https://www.sec.gov/).



    Fast Track Solutions Inc.
    ian@fasttracksolutionsinc.com
    
    View Full Article Hide Full Article
    • As a general screening for all-comers (i.e. COVID-19 symptomatic and asymptomatic populations), COVISTIX (n=783) has an 81% sensitivity vs. 62% (n=2202) sensitivity by globally leading Panbio rapid antigen test.

    SAN DIEGO, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN (The Institute of National Genomics Medicine, Mexico).

    Detailed results can be found at: https://www.medrxiv.org/content/10.1101/2021.09.10.21263410v1

    • As a general screening for all-comers (i.e. COVID-19 symptomatic and asymptomatic populations), COVISTIX (n=783) has an 81% sensitivity vs. 62% (n=2202) sensitivity by globally leading Panbio rapid antigen test.

    SAN DIEGO, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN (The Institute of National Genomics Medicine, Mexico).

    Detailed results can be found at: https://www.medrxiv.org/content/10.1101/2021.09.10.21263410v1

    "Analytical performances of the COVISTIX™ and Panbio™ antigen rapid tests for SARS-CoV-2 detection in an unselected population (all comers)"

    Key highlights include:

    • For the population tested with COVISTIX™ (n=783), sensitivity and specificity were 81% (CI95% 76.0-85.0) and 96.0% (CI95% 94.0-98.0), respectively. In contrast, the sensitivity of the Panbio comparator test (n=2202) was measured at 62% (CI95%: 58.0-64.0%) and specificity at 99.0% (CI95%: 0.99-1.00).

    This finding is significant as higher COVISTIX sensitivity means fewer false negatives, which is essential to managing the spread of COVID virus infection and preventing the COVID disease, in particular those cases linked to highly transmissible variants of concern such as the Delta variant. Additionally, this superior sensitivity result is quite impressive in a real-world population of all-comers (vs in only symptomatic patients) utilizing an initial shallow nasal sampling protocol followed by an optional nasopharyngeal sampling, if desired.

    About Sorrento Therapeutics, Inc.

    Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

    Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

    For more information visit www.sorrentotherapeutics.com.

    Forward-Looking Statements

    This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's technologies and product candidates, including, but, not limited to, Sorrento's COVISTIX diagnostic test; the specificity and sensitivity of COVISTIX; the potential for COVISTIX to offer fewer false negative results, including in cases involving a SARS-CoV-2 variant of concern; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects, including, but not limited to risks related to conducting clinical studies and seeking regulatory approval for COVISTIX; the clinical and commercial success of COVISTIX; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

    Media and Investor Relations Contact

    Alexis Nahama, DVM (SVP Corporate Development)

    Email: mediarelations@sorrentotherapeutics.com

    Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB™, DAR-T™, SOFUSA™, MuVAXX™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

    ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

    All other trademarks are the property of their respective owners.

    ©2021 Sorrento Therapeutics, Inc. All Rights Reserved. 



    Primary Logo

    View Full Article Hide Full Article
  2. SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) --  Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualconference). The conference is being held virtually on September 13-15, 2021.

    Dr. Henry Ji, Chairman and CEO of Sorrento, will provide corporate updates and highlights associated with Sorrento's product pipeline in the strategic focus areas of the company: COVID-19, Cancer and Autoimmune Therapeutics, and Non-Opioid Pain Management.

    COVID-19 Product Portfolio Highlights:

    • COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS. Regulatory…

    SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) --  Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualconference). The conference is being held virtually on September 13-15, 2021.

    Dr. Henry Ji, Chairman and CEO of Sorrento, will provide corporate updates and highlights associated with Sorrento's product pipeline in the strategic focus areas of the company: COVID-19, Cancer and Autoimmune Therapeutics, and Non-Opioid Pain Management.

    COVID-19 Product Portfolio Highlights:

    • COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS. Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization.         
    • COVIDROPS (STI-2099): Intranasal neutralizing antibody (nAb) formulation in Phase 2 trials in UK, US and soon in Mexico for newly diagnosed COVID patients in an outpatient setting.
    • COVI-AMG (STI-2020): Potentially highly potent/low dose antibody in a 2 minute IV-push in Phase 2 trials for systemic treatment in an outpatient setting.
    • COVISHIELD antibody (STI-9167): Demonstrating potent in vitro virus neutralization across all currently known variants of concern (VoCs) and reducing replicating virus in the lungs of infected transgenic K18 mice (with human ACE2 receptor) to undetectable levels (following infection by SARS-CoV-2 WA-1 strain or VoCs including Alpha, Beta, Gamma, Delta, and Lambda).
    • MPI-8 and its SAR-Improved Analog (1121): Small molecule antiviral targeting SARS-CoV-2 main protease, demonstrating broad-spectrum, potent antiviral activities against SARS-CoV-2 and all currently known VoCs.
    • Multivalent mRNA COVID-19 Vaccine: Elicited a stronger humoral immune response against Delta VoC as compared to SARS-CoV-2 intramuscular mRNA vaccine in preclinical studies.
    • Recombinant RBD Subunit Vaccine: Demonstrated strong humoral immune response against WA-1 and Delta VoC in preclinical studies.
    • Abivertinib: Phase 2 studies for treatment of acute respiratory distress syndrome (ARDS) in hospitalized COVID patients in US (96 Pts) and Brazil (400 Pts) are completed.
    • COVI-MSC: Phase 2 for ARDS in ICU COVID patients are ongoing in US and Brazil.

    Cancer and Autoimmune Product Portfolio Highlights:

    • Abivertinib: Phase 3 topline data in NSCLC available Q4 2021.
    • Abivertinib: IND for Phase 2 in Prostate Cancer to be filed Q4 2021.
    • PD-L1 antibody: In Phase 3 for SCLC and NDA submission in China for recurrent or metastatic cervical cancer.
    • CD38 ADC: In Phase 1 for Amyloidosis and Multiple Myeloma.
    • CD38 DAR-T: In Phase 1 for Relapsed and Refractory Multiple Myeloma.
    • CD47 antibody: In Phase 1 in solid tumors.
    • SOFUSA: Lymphatic delivery of Enbrel in Phase 1b in refractory rheumatoid arthritis patients.

    Non-Opioid Pain Management Product Portfolio Highlights:

    • ZTlido: Commercial with strong sales growth and expanded coverage for up to 65% of lives nationally.
    • SP-102: Phase 3/pivotal trial (US) completed full enrollment.
    • Resiniferatoxin (RTX): In Phase 2 for Osteoarthritis pain management.
    • RTX: In Phase 2 trial for intractable cancer pain (pending FDA clearance).

    An updated corporate presentation will also be available at www.sorrentotherapeutics.com

    About Sorrento Therapeutics, Inc.

    Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

    Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase 1b trial for intractable pain associated with cancer and a Phase 1b trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

    For more information visit www.sorrentotherapeutics.com.

    Forward-Looking Statements

    This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical and clinical studies and seeking regulatory approval for COVISTIX, COVIDROPS, COVI-AMG, COVISHIELD, MPI-8, Multivalent mRNA COVID-19 Vaccine, Recombinant RBD Subunit Vaccine, Abivertinib, COVI-MSC, anti-PD-L1 antibody, anti-CD38 Antibody Drug Conjugate, CD38 DAR-T, anti-CD47 antibody, the Sofusa Lymphatic Delivery System, SP-102 and Resiniferatoxin, including the timing for receipt of any such approval; conducting and receiving results of clinical trials; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19 and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

    Media and Investor Relations Contact

    Alexis Nahama, DVM (SVP Corporate Development)

    Email: mediarelations@sorrentotherapeutics.com

    Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB™, DAR-T™, SOFUSA™, MuVAXX™, COVI-AMG™, COVIDROPS™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

    ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

    All other trademarks are the property of their respective owners.

    ©2021 Sorrento Therapeutics, Inc. All Rights Reserved.



    Primary Logo

    View Full Article Hide Full Article
    • First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.

    • Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.

    SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil. This study (MSC-COV-202BR) is a multi-arm, randomized, placebo-controlled Phase 2 study of the efficacy and safety of three infusions of COVI-MSC administered…

    • First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.



    • Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.

    SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil. This study (MSC-COV-202BR) is a multi-arm, randomized, placebo-controlled Phase 2 study of the efficacy and safety of three infusions of COVI-MSC administered on varying schedules in the setting of standard of care treatments for COVID-19 in 100 subjects. The primary objective of this study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS. 

    Additionally, Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC:

    1. A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites in the United States.
    2. A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil.

    Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated, "It brings us great pleasure to see our MSC treatments for COVID-19-induced ARD/ARDS and post-COVID pulmonary long-haul syndrome rapidly move forward in clinical trials and towards a potential emergency approval of this promising therapy globally. We believe that COVI-MSC can help save lives, which is our primary goal at Sorrento."

    More information on the three Phase 2 trials can be found at www.clinicaltrials.gov (NCT04903327, NCT04905836 and NCT04992247).  

    Mesenchymal stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage. More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2.

    Personalized Stem Cells, Inc. (PSC) is Sorrento's GMP manufacturing partner for COVI-MSC. 

    About Sorrento Therapeutics, Inc.

    Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

    Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

    For more information visit www.sorrentotherapeutics.com.

    Forward-Looking Statements

    This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the clinical testing of a human allogeneic adipose-derived MSC product candidate (COVI-MSC) in a Phase 2 placebo-controlled study in Brazil; the continued enrollment of the Phase 2 clinical trial at multiple sites in Brazil for COVI-MSC; the plans to conduct additional Phase 2 studies across multiple sites in the US and Brazil; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects, including, but not limited to risks related to seeking regulatory approval for COVI-MSC in the US and Bazil; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

    Media and Investor Relations Contact

    Alexis Nahama, DVM (SVP Corporate Development)

    Email: mediarelations@sorrentotherapeutics.com

    Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

    ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

    All other trademarks are the property of their respective owners.

    ©2021 Sorrento Therapeutics, Inc. All Rights Reserved.



    Primary Logo

    View Full Article Hide Full Article
  3. Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance and growth plan.

    "The appointment of these five…

    Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance and growth plan.

    "The appointment of these five all-star independent directors marks a major milestone for the Company," commented Ian James, Chief Executive Officer and Director of Better For You Wellness. "This diverse group of new Directors brings a vast pool of strategic guidance from many different industries and professional backgrounds, which will lend itself to the Company's aggressive growth plan. Furthermore, the Company's 5:2 majority of non-executive independent directors means that Better For You Wellness, Inc. is one step closer to meeting the listing requirements for up-listing to a national securities exchange such as the NASDAQ or NYSE." 

    Additional information about the New Directors can be found below:

    Montel Williams

    Montel Williams earned his media celebrity status as an Emmy Award winning television personality and radio talk show host. Mr. Williams is also a decorated Naval officer, inspirational speaker, author, wellness entrepreneur and health advocate. Additionally, Mr. Williams was a Founder of Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotechnology company that focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Mr. Williams was also the Founder of the Montel Williams MS Foundation, a 501(c)(3) organization devoted to researching Multiple Sclerosis and helping people suffering from Multiple Sclerosis. Mr. Williams enlisted in the United States Marine Corps in 1974. Mr. Williams received a B.S. in Engineering from the United States Naval Academy in 1980, and served in the United States Navy in active duty until 1991, and as a reservist until 1996 when he retired at the rank of Lieutenant Commander. Mr. Williams' awards include two Meritorious Service Medals, two Navy Commendation Medals, the National Defense Service Medal, the Navy Achievement Medal, two Navy Expeditionary Medals, the Armed Forces Expeditionary Medal and two Humanitarian Service Medals.

    Leslie Bumgarner

    With decades of executive-level experience in the financial industry, Leslie Bumgarner is the President and CEO of and Chief Executive Officer of Telhio Credit Union, a $1.3 billion financial cooperative serving Central and Southwest Ohio. Ms. Bumgarner has served as a volunteer with Ronald McDonald House Charities of Central Ohio since 2010 and currently serves as the Vice Chair of the Board of Trustees. Ms. Bumgarner also serves as a member of the Executive Committee of the Hamilton, Ohio Chamber of Commerce and serves as Vice Chair of the Board of Cooperative Business Services, a commercial lending institution. Ms. Bumgarner received a B.S. in Business Administration in 1979 from Ohio State University.

    Joseph Watson

    With decades of executive-level experience as a leader and visionary in the pet industry, Joseph Watson is President and Chief Executive Officer of Petland, Inc., a global pet products retailer with stores in eight countries. Mr. Watson began at Petland as Vice President of Operations in November 2005 and then served as Chief Operating Officer prior to becoming CEO. Since July 2015, Mr. Watson is a member of the Board of Trustees of Shawnee State University and serves as the Chairman of the Board of Trustees of Adena Health System, a medical services provider with four hospitals and six regional clinics in Ohio. Mr. Watson served in the United States Army from 1985 to 1987 and is also a National Guard veteran. Mr. Watson received a B.S. in Communications System Management from Ohio University in 1992, and received a Master's in Business Administration from Ohio University in 1999.

    David Deming


    With decades of senior-level investment banking experience, David Deming serves as Partner and Chief Operating Officer of ID Fund LLC, an investor-directed firm for accredited investors. Mr. Deming formerly served as a director of Sorrento Therapeutics Inc. (NASDAQ:SRNE), a clinical stage and commercial-stage biopharmaceutical company that develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases, and has served on the board of numerous other public and private biotechnology companies, in addition to serving on the Board of Trustees of Hobart and William Smith Colleges for over a decade. Mr. Deming started fis career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College in 1975.

    Dr. Nicola Finley, MD


    As a board certified internal medicine physician with decades of experience as a practicing physician, Dr. Nicola R. Finley currently serves as Adjunct Faculty in the Health Promotion Sciences Division at the Mel and Enid Zuckerman College of Public Health at the University of Arizona, where she lectures to undergraduate, graduate and medical students, and presents to staff and faculty on the topic of personal wellness. Dr. Finley also serves as an Advisory Board Member of the Global Wellness Summit, an organization that gathers leaders and visionaries in the wellness industry, and serves as an Advisory Council Member at Luma Wealth, a wealth management firm that focuses on advising women and their families. Dr. Finley also serves as a Community Advisory Board Member of Arizona Public Media, a Southern Arizona-based non-profit public media service providing television and radio content including NPR and PBS to the area. Dr. Finley has had her research published in the American Journal of Lifestyle Medicine and Current Sexual Health Reports. Dr. Finley authored Function: A multidimensional view for the International Council on Active Aging®, and wrote the chapter on "Women's Sleep" in Integrative Sleep Medicine published by Weil Integrative Medicine Library. Dr. Finley received a B.A. in Educational Studies from Brown University in 1994, and received a M.D. from the George Washington University School of Medicine in 1998.

    Further to the Company's press release on August 19, 2021, The Company's name change from Fast Track Solutions, Inc. to Better For You Wellness, Inc. (the "Name Change") has become effective in the State of Nevada. The Company is still awaiting notification from FINRA that the Name Change has been processed. The Company is actively exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. 

    About Better For You Wellness, Inc.

    Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) is a Columbus, Ohio-based blank-check company that is exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. Learn more at https://betterforyouwellness.com/.

    Forward-Looking Statements

    This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could," "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed with SEC (https://www.sec.gov/).

    Attachment



    Fast Track Solutions Inc.
    ian@fasttracksolutionsinc.com
    
    View Full Article Hide Full Article
View All Sorrento Therapeutics Inc. News